A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood
Status:
Not yet recruiting
Trial end date:
2023-05-05
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to investigate the relative bioavailability of BI 425809
given alone (Reference) compared to a combined administration with the moderate CYP3A4
inducer bosentan (Test) following repeated oral administration.